SUN PHARMA CANADA
GenericsSUN PHARMA CANADA is a generic drug manufacturer focused on Dermatology, Immunology, Gastroenterology.
SUN PHARMA CANADA's Key Drugs
SUN PHARMA CANADA's core commercial portfolio centers on ADAPALENE AND BENZOYL PEROXIDE, CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE, HALOBETASOL PROPIONATE AND TAZAROTENE, spanning Dermatology and Immunology — its most strategically important drugs approved in the last 15 years.
SUN PHARMA CANADA's Recent FDA Approvals
New NDA/BLA approvals for SUN PHARMA CANADA over the last two years — novel drugs only, excluding generics and label supplements.
SUN PHARMA CANADA's Therapeutic Areas
SUN PHARMA CANADA's approved drugs and pipeline span 5 therapeutic areas, led by Dermatology and Immunology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
SUN PHARMA CANADA's Top Competitors
SUN PHARMA CANADA's closest competitors by therapeutic-area and drug-target overlap include BAUSCH, Pfizer, and BAUSCH AND LOMB INC. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
SUN PHARMA CANADA Pipeline Snapshot
Active clinical trials for SUN PHARMA CANADA across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • ADAPALENE AND BENZOYL PEROXIDE leads revenue
- • 3 key drugs tracked
Trial Catalysts
- • Dermatology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (3)
Discontinued (0)
Company Info
- First Approval
- 1978-07-24
- Latest
- 2026-04-28
- Applications
- 141